Why the study?
The benefit of beta-blockers for myocardial infarction patients with preserved left ventricular ejection fraction is uncertain, especially in the era of modern revascularization.
Do beta-blockers reduce the composite of all-cause mortality and myocardial infarction in patients with myocardial infarction and preserved left ventricular ejection fraction?
Do beta-blockers reduce the composite of all-cause mortality and myocardial infarction in patients with myocardial infarction and preserved left ventricular ejection fraction?
Beta-blockers do not appear to provide significant clinical benefit in reducing mortality or recurrent ischemic events in patients with myocardial infarction and preserved ejection fraction.
No takes yet. Share an insight, caveat, or question.
Beta-blockers confer no outcome benefit in MI with preserved LVEF; challenges routine use and supports guideline reevaluation.
Sabina et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: